National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure

References

• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269.
   PubMed Web of Science ®Google Scholar
• Menting SP, Coussens E, Pouw MF, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol. 2015;151(6):616–622.
   PubMed Web of Science ®Google Scholar
• Di Altobrando A, Magnano M, Offidani A, et al. Deferred time of delivery of biologic therapies in patients with stabilized psoriasis leads to a ‘perceived satisfaction’: a multicentric study. J Dermatolog Treat. 2020;29:1–5.
   Google Scholar
• Atalay S, Reek J, Otero M, et al. Health economic consequences of a tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab compared with standard psoriasis care: a cost-utility analysis of the CONDOR study. Acta Derm Venereol. 2020;100(19):adv00340.
   PubMedGoogle Scholar
• Michielsens CAJ, van Muijen ME, Verhoef LM, et al. Dose tapering of biologics in patients with psoriasis: a scoping review. Drugs. 2021;81(3):349–366.
   PubMed Web of Science ®Google Scholar
• Llamas-Velasco M, Daudén E. Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival. Dermatol Ther. 2020;33(6):e14134.
   PubMed Web of Science ®Google Scholar
• Sanz-Gil R, Pellicer A, Montesinos MC, et al. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish university hospital. J Dermatolog Treat. 2020;31(4):370–377.
   PubMed Web of Science ®Google Scholar
• Atalay S, van der Schoot LS, Vandermaesen L, et al. Evaluation of a one-step dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis in daily practice. Acta Derm Venereol. 2021;101(5):adv00463.
   PubMedGoogle Scholar
• Hansel K, Bianchi L, Lanza F, et al. Adalimumab dose tapering in psoriasis: predictive factors for maintenance of complete clearance. Acta Derm Venereol. 2017;97(3):346–350.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Gisondi P, De Simone C, et al. Down-titration of adalimumab and etanercept in psoriatic patients: a multicentre observational study. Acta Derm Venereol. 2016;96(2):251–252.
   PubMed Web of Science ®Google Scholar
• Atalay S, van den Reek J, den Broeder AA, et al. Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial. JAMA Dermatol. 2020;156(4):393.
   PubMed Web of Science ®Google Scholar
• Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate to severe plaque psoriasis: results from the randomised, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304–315.
   PubMed Web of Science ®Google Scholar
• Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179(2):320–328.
   PubMed Web of Science ®Google Scholar
• Ye LR, Yan BX, Chen XY, et al. Extended dosing intervals of ixekizumab for psoriasis: a single-center, uncontrolled, prospective study. J Am Acad Dermatol. 2022;86(6):1348–1350.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Maurelli M, Bellinato F, et al. Is risankizumab as needed administration a good option for patients with plaque psoriasis? J Euro Acad Dermatol Venereol. 2022;36(9):e713–e715.
   PubMed Web of Science ®Google Scholar
• Hamadah IR, Al Raddadi AA, Bahamdan KA, et al. Saudi practical guidelines on biologic treatment of psoriasis. J Dermatolog Treat. 2015;26(3):223–229.
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• van Muijen ME, van der Schoot LS, Bovenschen HJ, et al. Dosisvermindering van biologics voor psoriasis. Nederlands Tijdschrift Voor Dermatologie en Venereologie. 2021;31(1):22–26.
   Google Scholar
• van Muijen ME, van der Schoot LS, van den Reek J, et al. Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide. Arch Dermatol Res. 2022;314(7):687–695.
   PubMed Web of Science ®Google Scholar
• Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med. 2011;8(1):e1000393.
   PubMed Web of Science ®Google Scholar
• Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401–409.
   PubMed Web of Science ®Google Scholar
• Ogrinc G, Davies L, Goodman D, et al. SQUIRE 2.0 (standards for QUality improvement reporting excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf. 2016;25(12):986–992.
   PubMed Web of Science ®Google Scholar
• Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325–1334.
   PubMed Web of Science ®Google Scholar
• Gerbens LA, Boyce AE, Wall D, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. Trials. 2017;18(1):87.
   PubMedGoogle Scholar
• De Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402.
   PubMedGoogle Scholar
• Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179(3):642–650.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158–1166.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–298.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Schwensen JF, Clemmensen A, Sand C, et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study. Dermatol Ther. 2017;30(6):e12550.
   PubMed Web of Science ®Google Scholar
• Liau MM, Oon HH. Therapeutic drug monitoring of biologics in psoriasis. Biologics. 2019;13:127–132.
   PubMed Web of Science ®Google Scholar